korrents
Ruxandra Teslo

What Ruxandra Teslo thinks about AI and science

@ruxandra-teslo · 14 positions · On ppll ↗

Geneticist by training and writer on science, medicine and policy. She holds a PhD in genomics, writes at Ruxandra's Substack and for Works in Progress, and co-founded Clinical Trial Abundance, a project arguing that the binding constraint on new medicines is how trials are run rather than how drugs are designed.

Ruxandra Teslo did not write this page.

We collected these quotes from things they published elsewhere, and every quote links to where it was said. They have no account here and have not endorsed this site. Quotes are word for word; the short line under each one is our own restatement, not their wording. Their own site. Is this you? Claim it or ask us to remove it. Or tell us what is wrong here.

Filter AI and science · Newest first
Topic
All 14AI and science 2innovation 2AI alignment 1design 1Psychotherapy 1venture capital 1
Sort
NewestOldest

Only Ruxandra Teslo on AI and science. See everyone on AI and science

2 dated positions, 2026, in their own words. Our reading of what Ruxandra Teslo has said — not written or endorsed by them.

2 positions so far — this page is not yet offered to search engines.

  1. Our readingAI will not on its own compress decades of medical progress into a few years, because the binding constraint is human data, clinical trials and regulation rather than intelligence.

    Their wordsI told him what I believe: that in the age of AI, medicine will be bottlenecked more than ever by regulation and the grind of clinical trials, and that billions poured into faster pre-clinical research won’t touch that problem, unsexy as it is.

    ↗Intelligence is not the main bottleneckwritingruxandrabio.com 1st of 6 in this piece

  2. 5 months earlier

  3. Our readingThe human data an AI model would need to predict trial outcomes can only come from trials in people, so the loop runs no faster than the trials themselves.

    Their wordsBut remember that such data can only come from trials in people (mice are nice, but most animal results simply do not translate.)

    ↗A response to Dario Amodei on AI & clinical trialswritingruxandrabio.com 5th of 5 in this piece